Agonist News and Research

RSS

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

Tirzepatide cuts body fat while preserving skeletal muscle in real-world study

2 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

Veterinary sedative in fentanyl supply spikes severe withdrawal cases

A powerful veterinary sedative, medetomidine, is increasingly infiltrating the street supplies of the already deadly opioid fentanyl, with patients suffering from its withdrawal quadrupling in recent years, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylvania.

29 Sep 2026

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal.

28 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd)-negative brain lesions.

26 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

New study highlights difficulty of detecting gastric ulcer pain in horses

A new study led by Australian veterinarians has exposed the challenge of identifying pain in horses with gastric ulcers and highlights an urgent need to better detect when horses are suffering.

23 Sep 2026

Looking for GLP-1 advice online? Likes may tell you less than you think

Researchers assessed 128 videos about GLP-1 medications on Douyin and Bilibili and found that Bilibili videos scored higher on two measures of reliability and transparency. Longer videos received higher quality scores, while popularity did not consistently reflect information quality.

21 Sep 2026

Study identifies bile acid that helps reduce excess fat accumulation in the liver

Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common condition that causes excess fat to build up in the liver, affecting about one-quarter of adults worldwide.

17 Sep 2026

Salk scientists demonstrate B cells directly enhance killer T cell function

Cancer is the second leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives them to innovations that revolutionize cancer care-innovations like immunotherapy.

17 Sep 2026

GLP-1 drugs and SGLT-2 inhibitors linked to slower kidney decline

The diabetes drugs glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs may also help to slow decline in kidney function in people with type 2 diabetes and albuminuria (high protein levels in the urine), finds a large US study published by The BMJ today.

17 Sep 2026

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

In a US multicenter electronic health record study, researchers compared tirzepatide with semaglutide in adults with asthma and type 2 diabetes, matching 8,176 patients in each treatment group. Asthma exacerbation risk was similar between treatments, while tirzepatide was associated with a lower likelihood of receiving a short-acting beta-agonist prescription.

14 Sep 2026

A study of ayahuasca users found a mental health pattern researchers cannot yet explain

In a cross-sectional study of 808 Brazilian adults planning to attend ayahuasca ceremonies, greater prior experience with the brew was associated with lower depression, anxiety, and stress scores, as well as higher spiritual well-being and stronger metaphysical beliefs. Because the study was observational and relied on self-reported data, it cannot show that ayahuasca caused these differences.

13 Sep 2026

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults

11 Sep 2026

Agonist News and Research

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

CBL-514 injection reduces visceral and subcutaneous fat in trials

Real-world data reveals higher reported GLP-1 side effects in female patients

Study examines the real-world use of GLP-1 RA drugs in children and young people

Petrelintide produces double-digit weight loss with fewer side effects

Veterinary sedative in fentanyl supply spikes severe withdrawal cases

New registry data shows semaglutide does not cause pancreatic cancer

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

Semaglutide cuts major heart events, but researchers still cannot fully explain why

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

Semaglutide’s heart benefits may extend beyond weight loss

New study highlights difficulty of detecting gastric ulcer pain in horses

Looking for GLP-1 advice online? Likes may tell you less than you think

Study identifies bile acid that helps reduce excess fat accumulation in the liver

Salk scientists demonstrate B cells directly enhance killer T cell function

GLP-1 drugs and SGLT-2 inhibitors linked to slower kidney decline

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

A study of ayahuasca users found a mental health pattern researchers cannot yet explain

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News